PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: The Scott Partnership

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Novozymes Biopharma and Upperton Limited Granted European Patent for Oncology Technology - Novozymes Biopharma and Upperton Limited today announce that the European Patent Office has confirmed the official Decision to Grant a European patent for their targeted drug delivery joint patent application (European patent No 1605979)
Novozymes Biopharma and Upperton Limited Granted European Patent for Oncology Technology

 

NewswireToday - /newswire/ - Nottingham, United Kingdom, 2009/02/18 - Novozymes Biopharma and Upperton Limited today announce that the European Patent Office has confirmed the official Decision to Grant a European patent for their targeted drug delivery joint patent application (European patent No 1605979).

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The decision, dated 27th October 2008, significantly strengthens the Upperton drug delivery technology portfolio and highlights the growing technology platform that it offers to partner companies. Upperton, along with its collaboration partner Novozymes Biopharma, is now seeking to exploit these technologies with established pharmaceutical companies.

The newly-granted patent describes methods of conjugating antibodies and other targeting agents to protein carriers by means of a heterobifunctional linker. In doing so, it is possible to deliver large quantities of drugs and other agents to selected sites in the body.

The initial focus for the technology will be in oncology. One such application involves using monoclonal antibodies to target recombinant albumin loaded with, for example, a chemotherapeutic agent to cancer cells. By using the carrier properties of albumin, it is possible to target significant quantities of chemotherapeutic agents or radioactive metal ions to cancer cells, whilst retaining the sensitive binding property of the targeting antibody. The result is a significant increase in the amount of therapeutic agent that can be delivered to its target compared to standard administration methods.

"We are pleased to include this latest patent to our expanding portfolio,'' said Richard Johnson, founding Director of Upperton, "We believe that this patent complements our rP-nano drug delivery platform, an emerging technology based on recombinant protein nanoparticles. The granting of this patent will add significantly to our current achievements with this technology."

Upperton is now in the process of seeking development partners to exploit its drug delivery platform. It is anticipated that the Upperton technology platform will add value across a wide a range of pharmaceutical applications. The current focus is in oncology but other areas that are growing in interest include the delivery of nucleic acids for the rapidly growing siRNA market.

The granting of the new patent underlines the growing relationship that Upperton is creating with its collaborative partner, Novozymes Biopharma. Dr. Johnson added: "I am extremely pleased to be continuing our collaboration with Novozymes Biopharma. Use of their animal-free, GMP recombinant proteins will be extremely important as we look to commercialise our unique technologies."

Dr. Dave Mead, Novozymes Biopharma's Business Development Director commented, "We are very pleased to continue collaborating with Upperton as we seek to develop these exciting technologies. This is further exemplification of Novozymes Biopharma's presence in the field of protein drug delivery systems as well as its high yielding expression systems being used for the production of pharmaceutical grade recombinant proteins."

For further press information please contact: Fiona Robinson, The Scott Partnership, 1 Whiteside, Station Road, Holmes Chapel, Cheshire CW4 8AA, United Kingdom T: +44 1477 539539 F: +44 1477 539540 E: novozymes[.]scottpr.com.

About Novozymes
Novozymes (novozymes.com) is the world leader in bioinnovation. Together with customers across a broad array of industries, we create tomorrow's industrial biosolutions, improving our customers' business and the use of our planet's resources.

With over 700 products used in 130 countries, Novozymes' bioinnovations improve industrial performance and safeguard the world's resources by offering superior and sustainable solutions for tomorrow's ever-changing marketplace.

Novozymes' natural solutions enhance and promote everything from removing trans-fats in food, to advancing biofuels to power the world tomorrow. Our never-ending exploration of nature's potential is evidenced by over 4,500 patents, showing what is possible when nature and technology join forces.

Our 4,500+ employees working in research, production and sales around the world are committed to shaping business today and our world tomorrow.

About Upperton Ltd.
Upperton Limited (upperton.com), founded in 1999, is a privately owned biotech company based in Nottingham, UK and specialising in spray drying and particle technologies. They have recently co-patented rP-nano technology with Novozymes as a next generation technology for producing nano-sized particles from proteins, with broad application. The rP-nano technology offers unique competitive advantages over current methods of producing nanoparticles. Upperton welcomes academic and industrial partners to explore and commercialise this technology.

Media Contacts:
Richard Johnson, Director
Upperton Ltd
T: +44 115 9553387
E: rjohnson[.]upperton.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: The Scott Partnership

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Novozymes Biopharma and Upperton Limited Granted European Patent for Oncology Technology

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Sally Kent / Fiona Robisnon 
+44 115 9551209 syke[.]novozymes.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any The Scott Partnership securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From The Scott Partnership / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  BizJobs.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)